Skip to content
  • Home
  • About
    • Management Team
    • Board of Directors
  • Pipeline
    • ENAC PULMONARY (VX-371/P-1037)
    • tPAD
    • Mucolytic Agents
    • CFTR Corrector Program for CF
    • P-321 Dry Eye Disease
    • Clinical Trials
  • News and Events
  • Partnerships
  • Careers
  • Contact

Parion Sciences

Parion Sciences Dry Eye Program Recognized by National Eye Institute (NEI)

October 2, 2014News & EventPaul Boucher
  • View Entire Article

Post navigation

← Parion Sciences Announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to Accelerate the Development of Novel CF Treatment Parion Sciences Announces $15.6 Million in Grant Support for Pulmonary Research Program →

Recent Posts

  • Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
  • Topical ENaC blocker serves as novel approach to tear film
  • Parion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis Conference
  • Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease
  • Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)

Recent Comments

    Archives

    • May 2017
    • November 2016
    • October 2016
    • July 2016
    • May 2016
    • January 2016
    • October 2015
    • September 2015
    • June 2015
    • May 2015
    • February 2015
    • November 2014
    • October 2014
    • September 2014
    • June 2014
    • May 2014
    • April 2014
    • November 2013

    Categories

    • News & Event
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    Home | About | Pipeline | News & Events | Partnerships | Careers | Contact

    Copyright © 2019. All Rights Reserved.

    Main menu
    AcceptParion uses cookies on this website with your consent to analyze traffic and to improve your user experience. For more information, including about the cookies we use and how to control cookies, please see our Privacy Policy. By continuing to surf on our website, you consent to the use of cookies. You can always opt out (e.g. by deleting the cookies), however, you may not be able to use the full functionalities of the website if you do.
    Privacy & Cookies Policy